Shopping Cart
Remove All
Your shopping cart is currently empty
Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate) is a broad-spectrum antifungal agent approved in Japan for treating onychomycosis, a fungal nail infection. It is a prodrug converted into ravuconazole.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $32 | - | In Stock | |
| 5 mg | $46 | - | In Stock | |
| 10 mg | $73 | - | In Stock | |
| 25 mg | $143 | - | In Stock | |
| 50 mg | $227 | - | In Stock | |
| 100 mg | $373 | - | In Stock | |
| 200 mg | $527 | - | In Stock |
| Description | Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate) is a broad-spectrum antifungal agent approved in Japan for treating onychomycosis, a fungal nail infection. It is a prodrug converted into ravuconazole. |
| In vitro | Fosravuconazole exhibits potent in vitro antifungal activity against a broad spectrum of fungal species, including Candida, Aspergillus, and Trichophyton species [1]. |
| In vivo | Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) suppresses parasitemia and prevents death in mice infected with the T. cruzi Y strain[2]. |
| Synonyms | E-1224 L-lysine ethanolate, BMS-379224 L-lysine ethanolate |
| Molecular Weight | 739.7 |
| Formula | C31H40F2N7O8PS |
| Cas No. | 914361-45-8 |
| Smiles | N#CC1=CC=C(C2=CSC([C@H](C)[C@@](OCOP(O)(O)=O)(C3=CC=C(F)C=C3F)CN4N=CN=C4)=N2)C=C1.CCO.N[C@H](C(O)=O)CCCCN |
| Relative Density. | no data available |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 48 mg/mL (64.89 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.7 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.